- Home
- TNGX vs FDUS Comparison
TNGX vs FDUS Comparison
Compare TNGX & FDUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- FDUS
- Stock Information
- Founded
- TNGX 2014
- FDUS 2011
- Country
- TNGX United States
- FDUS United States
- Employees
- TNGX N/A
- FDUS N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- FDUS Finance/Investors Services
- Sector
- TNGX Health Care
- FDUS Finance
- Exchange
- TNGX Nasdaq
- FDUS Nasdaq
- Market Cap
- TNGX 723.2M
- FDUS 745.8M
- IPO Year
- TNGX N/A
- FDUS 2011
- Fundamental
- Price
- TNGX $7.58
- FDUS $20.37
- Analyst Decision
- TNGX Strong Buy
- FDUS Buy
- Analyst Count
- TNGX 6
- FDUS 3
- Target Price
- TNGX $10.00
- FDUS $21.67
- AVG Volume (30 Days)
- TNGX 2.6M
- FDUS 268.0K
- Earning Date
- TNGX 11-05-2025
- FDUS 10-30-2025
- Dividend Yield
- TNGX N/A
- FDUS 11.09%
- EPS Growth
- TNGX N/A
- FDUS N/A
- EPS
- TNGX N/A
- FDUS 2.31
- Revenue
- TNGX $24,296,000.00
- FDUS $152,305,000.00
- Revenue This Year
- TNGX $20.42
- FDUS $6.31
- Revenue Next Year
- TNGX N/A
- FDUS $5.37
- P/E Ratio
- TNGX N/A
- FDUS $8.81
- Revenue Growth
- TNGX N/A
- FDUS 8.16
- 52 Week Low
- TNGX $1.03
- FDUS $16.70
- 52 Week High
- TNGX $8.80
- FDUS $23.55
- Technical
- Relative Strength Index (RSI)
- TNGX 51.87
- FDUS 39.09
- Support Level
- TNGX $7.66
- FDUS $20.05
- Resistance Level
- TNGX $8.80
- FDUS $20.50
- Average True Range (ATR)
- TNGX 0.51
- FDUS 0.34
- MACD
- TNGX -0.04
- FDUS -0.02
- Stochastic Oscillator
- TNGX 33.70
- FDUS 25.40
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About FDUS Fidus Investment Corporation
Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investments is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.